Free tool
FAERS Monitor: Ongentys
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212489 or its brand name (Ongentys, Opicapone). Reports on generic versions are filed under their own applications.
Reports
2,446
Serious
1,874
77% of reports
Hospitalization
1,038
Death reported
250
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hallucination339
- dyskinesia338
- fall291
- on and off phenomenon196
- tremor163
- death150
- gait disturbance143
- drug ineffective134
- confusional state130
- parkinson^s disease127
- fatigue119
- hallucination, visual116
- dizziness112
- mobility decreased112
- anxiety111
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 21 |
| 2018 | 40 |
| 2019 | 61 |
| 2020 | 177 |
| 2021 | 567 |
| 2022 | 277 |
| 2023 | 243 |
| 2024 | 258 |
| 2025 | 358 |
| 2026 | 443 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,713 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| on and off phenomenonSignal | 196 | 314.7 | 274.4 | 58,834 |
| dyskinesiaSignal | 338 | 72.1 | 65.3 | 23,478 |
| hallucination, visualSignal | 116 | 47.5 | 39.7 | 5,210 |
| hallucinationSignal | 339 | 38.8 | 35.2 | 12,451 |
| mobility decreasedSignal | 112 | 13.4 | 11.2 | 1,278 |
| tremorSignal | 163 | 8.5 | 7.3 | 1,071 |
| fallSignal | 291 | 7.5 | 6.8 | 1,665 |
| confusional stateSignal | 130 | 6.9 | 5.9 | 657 |
| gait disturbanceSignal | 143 | 6.4 | 5.5 | 656 |
| anxietySignal | 111 | 3.4 | 2.8 | 184 |
| dizziness | 112 | 1.9 | 1.6 | 51 |
| death | 150 | 1.5 | 1.3 | 25 |
| fatigue | 119 | 1.3 | 1.1 | 9 |
| drug ineffective | 134 | 0.9 | 0.7 | 2 |
| parkinson^s disease | 127 | 0.0 | 0.0 | 1,084,453 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.